Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of medicines for cancer and proliferative diseases. Their product pipeline includes fadraciclib, a cyclin dependent kinase inhibitor in Phase 1/2 clinical trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase inhibitor in Phase 1/2 trials for advanced leukemias and solid tumors. Additionally, they are developing Sapacitabine, an oral prodrug for acute myeloid leukemia and myelodysplastic syndrome, and seliciclib, a CDK inhibitor in Phase 2 trials for Cushing's disease and rheumatoid arthritis.

Products

• Fadraciclib

• CYC140

• Sapacitabine

• Seliciclib